Advertisement
Screener

Moleculin Biotech, Inc. (MBRX) Increase (Decrease) in Accounts Payable and Accrued Liabilities

2.8 / 5 stars · 68/120 Roast Me

Moleculin Biotech, Inc. Increase (Decrease) in Accounts Payable and Accrued Liabilities

Moleculin Biotech, Inc. (MBRX) reported Increase (Decrease) in Accounts Payable and Accrued Liabilities of $285.00 thousand for the 9-month period ending 2017-09-30, per its 10-Q filed 2017-11-13.

Discontinued › Cash Flow › Operating Activities

us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities · last filed 2017-11-13

  • Moleculin Biotech, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2017-09-30 was $445.00K, a 61.82% increase year-over-year.
  • Moleculin Biotech, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2017-06-30 was -$209.00K.
  • Moleculin Biotech, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2017-03-31 was $49.00K, a 22.50% increase year-over-year.
  • Moleculin Biotech, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2016-12-31 was $105.87K.
  • Moleculin Biotech, Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2016 was -$41.13K.
Period endIncrease (Decrease) in Accounts Payable and Accrued Liabilities 2 monthIncrease (Decrease) in Accounts Payable and Accrued Liabilities 3 monthIncrease (Decrease) in Accounts Payable and Accrued Liabilities 3 month as first filedIncrease (Decrease) in Accounts Payable and Accrued Liabilities 5 monthIncrease (Decrease) in Accounts Payable and Accrued Liabilities 6 monthIncrease (Decrease) in Accounts Payable and Accrued Liabilities 6 month as first filedIncrease (Decrease) in Accounts Payable and Accrued Liabilities 9 monthIncrease (Decrease) in Accounts Payable and Accrued Liabilities 9 month as first filedIncrease (Decrease) in Accounts Payable and Accrued Liabilities 12 month
2017-09-30$445.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-13
$236.00K
derived: sum of 2 quarters · filed 2017-11-13
$285.00K
10-Q · filed 2017-11-13
$390.87K
derived: sum of 4 quarters · filed 2017-11-13
2017-06-30-$209.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-11
-$160.00K
10-Q · filed 2017-08-11
-$54.13K
derived: sum of 3 quarters · filed 2017-08-11
$220.87K
derived: sum of 4 quarters · filed 2017-11-13
2017-03-31$49.00K
10-Q · filed 2017-05-12
$154.87K
derived: sum of 2 quarters · filed 2017-05-12
$429.87K
derived: sum of 3 quarters · filed 2017-11-13
-$32.13K
derived: sum of 4 quarters · filed 2017-11-13
2016-12-31$105.87K
derived: 10-K 12 month − 10-Q 9 month · filed 2017-04-03
$380.87K
derived: sum of 2 quarters · filed 2017-11-13
-$81.13K
derived: sum of 3 quarters · filed 2017-11-13
-$41.13K
10-K · filed 2017-04-03
2016-09-30$275.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-13
-$187.00K
derived: sum of 2 quarters · filed 2017-11-13
-$147.00K
10-Q · filed 2017-11-13
-$146.80K
10-Q · filed 2016-11-21
2016-06-30-$462.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-11
-$422.00K
10-Q · filed 2017-08-11
-$421.94K
10-Q · filed 2016-08-15
2016-03-31$40.00K
10-Q · filed 2017-05-12
$40.21K
10-Q · filed 2016-06-16
2015-12-31$322.79K
10-K · filed 2017-04-03
2015-09-30$63.01K
10-Q · filed 2016-11-21

Similar stocks

Stock NameCountryMarket CapPE Ratio
MetaVia Inc. (MTVA)United States$0.011B-0.65
KALA BIO, Inc. (KALA)United States$0.011B-3.33
Theriva Biologics, Inc. (TOVX)United States$0.011B
Dare Bioscience, Inc. (DARE)United States$0.011B
Azitra, Inc. (AZTR)United States$0.010B-0.81
Medicus Pharma Ltd. (MDCX)$0.010B
KIORA PHARMACEUTICALS INC (KPRX)United States$0.012B
Scienture Holdings, Inc. (SCNX)United States$0.012B-0.38
Aprea Therapeutics, Inc. (APRE)United States$0.010B-0.78
Phio Pharmaceuticals Corp. (PHIO)United States$0.012B-0.92